Optimizing Rheumatology AIM Specialty Health Integration

Klivira's platform delivers robust rheumatology AIM Specialty Health integration, automating the complex prior authorization workflows for high-cost biologics, infusion therapies, and advanced imaging.

For revenue cycle directors and prior authorization coordinators in rheumatology, managing PAs for advanced therapies is a significant operational challenge. AIM Specialty Health, as a specialty benefit manager, often oversees these critical approvals. Klivira streamlines this process, ensuring compliance with payer-specific requirements and accelerating time-to-treatment.

Navigating Rheumatology Prior Authorizations with AIM Specialty Health

Rheumatology practices frequently encounter AIM Specialty Health for prior authorizations related to specialty drugs and advanced diagnostics. These include high-cost biologics like Humira, Enbrel, Stelara, Skyrizi, Rinvoq, as well as JAK inhibitors and infusion therapies. Klivira's integration simplifies the submission process, addressing the specific data requirements of AIM Specialty Health.

Key Rheumatology PA Triggers Managed by AIM Specialty Health

Biologics: TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab), Non-TNF biologics (e.g., tocilizumab, secukinumab, guselkumab).
JAK Inhibitors: tofacitinib, baricitinib, upadacitinib, often requiring prior TNF inhibitor failure.
Infusion Therapy: Provider-administered biologics and other intravenous agents.
Advanced Imaging: MRI for inflammatory arthritis assessment.
DEXA Scans: For osteoporosis management in chronic steroid patients.

Streamlining Documentation for AIM Submissions in Rheumatology

Rheumatology prior authorizations demand precise and comprehensive clinical documentation, frequently guided by ACR Treatment Guidelines. Klivira's platform ensures that all necessary data points are captured and submitted, reducing the likelihood of denials. This includes disease-specific criteria, activity scores, and prior treatment history.

Critical Documentation for AIM Rheumatology PAs

Diagnosis Documentation: ICD-10 codes with specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA).
Disease Activity Assessment: DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE.
Prior Conventional DMARD Trial: Documentation of methotrexate, sulfasalazine, or other csDMARD trial and response/contraindication.
Step Therapy Compliance: Evidence of failure or contraindication to required prior agents, including biosimilar substitution mandates.
Screening Completion: TB, hepatitis B/C, and immunization status for immunosuppressive biologics.

Klivira's Integration with AIM Specialty Health for Rheumatology Workflows

Klivira's integration capabilities automate the data exchange required by AIM Specialty Health, often leveraging X12 278 transactions or ePA portals. Our platform incorporates ACR-guideline-aware policy logic for step therapy sequencing and biosimilar substitution routing, which is crucial given the variability in payer policies. This ensures that submissions are accurate and compliant from the outset.

Addressing Common Denial Reasons Proactively

Many rheumatology PA denials stem from incomplete step therapy documentation, biosimilar substitution requirements, or missing disease activity scores. Klivira's system proactively identifies these gaps before submission, guiding users to provide the necessary information. This also includes managing the ongoing PA burden for chronic treatments and distinguishing between medical and pharmacy benefit routes for the same agent.

Frequently asked questions

How does Klivira handle biosimilar mandates from AIM Specialty Health for rheumatology drugs?

Klivira's payer-policy logic incorporates per-payer biosimilar mandates. For rheumatology, our system routes submissions according to specific biosimilar substitution requirements, ensuring compliance and reducing denials related to brand-name biologic requests when a biosimilar is mandated.

What EMR data is crucial for rheumatology AIM Specialty Health prior authorizations?

Key EMR data includes ICD-10 diagnoses, disease activity scores (e.g., DAS28, SLEDAI), documentation of prior DMARD trials, screening results (TB, hepatitis), and immunization records. Klivira integrates with your EMR to extract and structure this data for efficient submission to AIM Specialty Health.

Does Klivira manage re-authorizations for chronic rheumatology treatments requiring AIM approval?

Yes, Klivira supports periodic re-authorization workflows for chronic rheumatology biologics. Our platform tracks approval expiry dates and prompts for the continuous documentation of disease response, which is essential for successful re-authorization submissions to AIM Specialty Health.

How does Klivira address step therapy requirements for AIM Specialty Health rheumatology PAs?

Klivira's platform is designed with ACR-guideline-aware policy logic to manage complex step therapy requirements. It guides users through the necessary sequence of prior agent trials, including specific TNF inhibitors or biosimilars, ensuring that all conditions for AIM Specialty Health approval are met.

Can Klivira differentiate between medical and pharmacy benefit for rheumatology biologics submitted to AIM?

Yes, Klivira's system is equipped to handle the medical-vs-pharmacy benefit split for rheumatology biologics. Depending on the administration mode (self-administered vs. provider-administered infusion) and payer policy, our platform routes the PA request appropriately, even for the same agent.